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Purpose  of review:  Gastroenteritis  is  caused  by  a wide  range  of  viral,  bacterial  and  parasitic  pathogens  and
causes  millions  of  deaths  worldwide  each  year,  particularly  in  infant  populations  in developing  countries.
Traditional  microbiological  culture  and  immunological  based  tests  are  time  consuming,  laborious  and
often  lack  diagnostic  speciﬁcity  and  sensitivity.  As a result  patients  can  receive  suboptimal  and/or  inap-
propriate  antimicrobial  treatment.  In  recent  years,  rapid  nucleic  acid  diagnostics  (NAD)  technologies  have
become  available  to complement  or even  bypass  and  replace  these  traditional  microbiological  culture
and  immunological  based  tests.
The main  purpose  of  this  review  is to describe  a number  of  recently  available  multiparametric  com-
mercial  tests,  to support  the  rapid  and  accurate  clinical  diagnosis  of  human  gastroenteritis.  These  state  ofntegrated  platforms the  art technologies  have  the  ability  to identify  a wide  range  of  microorganisms  associated  with  enteric
gastroenteritis.  Following  further  technological  innovation  and  more  comprehensive  clinical  validation
studies,  these  NAD  tests  have  the potential  to impact  on  the  economic  burden  of  health  care  systems.
These  rapid NAD  tests  can  also  be  used  to guide  improved  patient  therapy  in  a  timely  manner  which  will
reduce  the  extent  of  morbidity  and  mortality  associated  with  these  infections  globally.
© 2014  Published  by  Elsevier  GmbH. Open access under CC BY-NC-ND license.ontents
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. Introduction
Gastroenteritis remains an important cause of morbidity and
ortality and accounts for signiﬁcant economic and societal loses
1]. Despite improved standards of living, advances in sanitation,
ater treatment and food safety awareness, an estimated 1.7 bil-
ion cases of diarrhoeal disease occur every year [2]. It is considered
mongst the leading causes of death in children in developing
ountries, and with infants under ﬁve years of age it is estimated
hat diarrhoeal disease accounts for approximately 2 million deaths
ach year [3,4].
Infectious gastroenteritis is caused by a wide range of microor-
anisms which makes diagnosis of the causative agent of infection
hallenging using traditional microbiological methods. In devel-
ped countries, viral pathogens are considered the most common
ause of gastroenteritis in humans [5]. Electron microscopy, and in
ore recent years antigen based tests have been widely used in
irology diagnostic laboratories [6,7]. These methods are laborious
nd lack speciﬁcity and/or sensitivity [5]. Bacterial gastroenteritis
lso remains a signiﬁcant cause of diarrhoeal disease worldwide
nd diagnosis is often limited to culturing on selective media, fol-
owed with a subsequent myriad of biochemical tests to identify the
ausative agent of infection. This can be time consuming (3–5 days),
ack speciﬁcity and relies on the cultivation of viable organisms
8]. Finally, enteric protozoa are also considered the most impor-
ant cause of parasitic infection [9]. Diagnosis of parasitic infection
ften relies on microscopy, which requires trained personnel and
n some instances cannot differentiate between pathogenic and
on-pathogenic species [10].
To address some of these difﬁculties in conventional gas-
roenteritis related diagnostics, a trend in recent years is
he development of suites of nucleic acid based ampliﬁcation
echniques (NAAT’s) to replace and/or complement traditional
icrobiological tests. Owing to the sensitivity, speciﬁcity and
eproducibility of test results, highly multiplexed NAD technolo-
ies are becoming the method of choice in many clinical diagnostics
aboratories [11]. In this review we aim to describe the current
tate of the art in molecular diagnosis of gastrointestinal infec-
ions. Particular emphasis is focused on multiparametric kits which
ffer highly multiplexed single test solutions for the identiﬁcation
f human associated gastrointestinal pathogens and also on algo-
ithmic based tests, whereby a series of successive diagnostics tests
ay  be performed to identify a causative agent of infection. Addi-
ional emphasis is also placed on fully integrated test platforms
.e. test platforms which have the capability to combine sample
reparation, ampliﬁcation, detection and reporting of the speciﬁc
icroorganism(s) present in a sample [12].
. Polymerase Chain Reaction
Since its discovery, the Polymerase Chain Reaction (PCR) has
ecome the molecular diagnostics cornerstone in clinical micro-
iology. In recent years it has been transformed by multiplex
eal-time PCR which allows for the rapid and accurate quantitative
etection of multiple targets in a single closed tube system [13,14].
here are a number of commercially available real-time PCR plat-
orms with single analyte detection kits available such as the Xpert
. difﬁcile (Cepheid), BD MAX  C.diff (Becton Dickenson). However, it
s  outside the scope of this review to describe all single gastroenteri-
is pathogen commercially available molecular based tests. Instead,
his review focuses on platforms and technologies that have a capa-
ility of detecting at least four microorganisms and/or associated
ntimicrobial drug resistance markers. Below we discuss a number
f advantages and disadvantages of a range of recent commercially
vailable test platforms, the list of which may  be non-exhaustive.on and Quantiﬁcation 1 (2014) 3–7
2.1. RIDA GENE-gastrointestinal kits
R-Biopharm (Darmstadt, Germany) offers a suite of Conformite
Europeene – in vitro diagnostic (CE-IVD) marked RIDA GENE-
Gastrointestinal kits which utilise multiplex real-time PCR and
multiplex reverse transcriptase real-time PCR to detect a range of
enteric pathogens (Table 1). Each individual kit has the ability to
detect and identify 3–4 bacteria, viruses and or parasitic pathogens
respectively [15]. An advantage of these rapid diagnostics tests is
that they have been validated on most common real-time PCR plat-
forms and hence can be readily adapted to many clinical diagnostics
laboratories for routine use [16]. A disadvantage of these tests is
that sample preparation is off line which means there is a require-
ment for external nucleic acid extraction and puriﬁcation by the
end user prior to use of the test.
2.2. EntericBio real-time Gastro Panel I
The EntericBio real-time Gastro Panel I (Serosep, Limerick,
Ireland) is a real-time PCR based kit that allows for the detection of
four bacterial enteric pathogens (Table 1). Brieﬂy, this test proce-
dure involves taking a swab from a stool sample and resuspending
in a nucleic acid sample preparation solution. The resuspended
sample is then heated to 97 ◦C for 30 min. Samples can then be auto-
matically transferred to wells containing lyophilised diagnostics
assay components and sealed. Subsequently, the diagnostics assay
is performed using a predeﬁned programme on a LightCycler 480
(Roche Diagnostics, Basel, Switzerland) which allows for the auto-
mated ampliﬁcation, detection and analysis of the data generated
[17]. A recent study has reported analytical speciﬁcities of 96–100%
and sensitivities of 100% depending on the pathogen present in a
sample [18]. The main advantage of this kit is that it can be used
directly on faecal samples and the sample throughput is high. How-
ever, a disadvantage of this test is the relatively low multiplexing
capacity.
2.3. Seeplex Diarrhea ACE detection
The Seeplex® Diarrhea ACE detection kit, by Seegene (Seoul,
Korea) is a multiplex PCR based test that allows for the detec-
tion and identiﬁcation of 14 viruses and bacteria (Table 1). The
test procedure encompasses reverse transcription, 3 multiplex PCR
assays utilising proprietary dual priming oligonucleotides (DPO)
and subsequent separation and detection of various size PCR prod-
ucts using a capillary electrophoresis device [19]. Recent studies
have reported analytical speciﬁcies of 96–100% and sensitivities of
40–100% depending on the pathogen present in a sample [19–21].
The main advantages of this test are the ability to detect both bac-
terial and viral enteric pathogens. A disadvantage of this kit is that
no parasitic pathogens are detected by the assays. Also nucleic acid
must be extracted and puriﬁed off line prior to use of this test [21].
2.4. Faecal pathogens A (16 plex)
AusDiagnostics (Beaconsﬁeld NSW, Australia) offers a multi-
parametric kit utilising multiplexed tandem PCR for the detection
of 16 faecal pathogens (Table 1) [22]. Brieﬂy, multiplex tandem
PCR consists of two  ampliﬁcation phases: Firstly a short (10–15
cycles) “primary ampliﬁcation”, which contains highly multiplexed
reactions is performed. These products are then diluted and sepa-
rated onto a 72 well base disc containing individual primer pairs
for each of the target microorganisms and subsequently “secondary
ampliﬁcation” for highly speciﬁc and sensitive ampliﬁcation of the
targets of interest. This secondary ampliﬁcation for each target
occurs in “tandem” as opposed to traditional multiplexing, which
allows for the use of one individual detection dye namely SYBR
K. Reddington et al. / Biomolecular Detection and Quantiﬁcation 1 (2014) 3–7 5
Table  1
Commercially available tests.
Test name
(manufacturer)
Turnaround
time  to
result
Technology  Regulatory
status (FDA
approved or
CE  marked)
Testing
location
Number of
multiparametric
analytes detected
Microorganism  panel portfolio
RIDA®GENE-kits
(R-Biopharm)
1.5 h per
test
Multiplex  (rt)
real-time  PCR
CE marked Centralised
laboratory
(high sample
throughput)
3–4 bacterial, virus
and  parasites per
test
RIDA®GENE Bacterial Stool Panel: Campylobacter
spp.,  Salmonella spp. and Y. enterocolitica
RIDA®GENE Hospital Stool Panel: norovirus GI/GII,
rotavirus and Clostridium difﬁcile toxin-genes A (tcdA)
and  B (tcdB)
RIDA®GENE EHEC/EPEC: Enterohämorrhagic E. coli
(EHEC), Enteropathogeic E. coli (EPEC)
RIDA®GENE ETEC/EIEC: Enterotoxic E. coli (ETEC) and
Enteroinvasive E. coli (EIEC)/Shigella spp.
RIDA®GENE Parasitic Stool Panel: Giardia lamblia,
Cryptosporidium parvum, Entamoeba histolytica and
Dientamoeba fragilis
EntericBio
real-time Gastro
Panel  I (Serosep)
∼1.5  h Multiplex
real-time PCR
CE marked Centralised
laboratory
(high sample
throughput)
4 bacterial
pathogens
Campylobacter spp. (C. jejuni, C. coli, and C. lari), Shiga
toxin-producing Escherichia coli (STEC) Shigella spp.,
and  Salmonella spp.
Seeplex  Diarrhea
ACE  detection
(Seegene)
∼10  h Multiplex (rt)
PCR
CE marked Centralised
laboratory
(high sample
throughput)
4–5 viruses and
bacteria  per test
The Seeplex Diarrhea-V assay: Astrovirus,
Adenovirus, Rotavirus A, Noroviruses GI/GII
The Seeplex Diarrhea-B1 assay: Salmonella spp.,
Shigella spp., Vibrio spp., Closrtidium difﬁcile (toxin B),
Campylobacter spp.
The  Seeplex Diarrhea-B2 assay: Clostridium
perfringens, Yersinia enterocolitica Aeromonas spp.,
E.  coli O157:H7 and Verocytotoxin-producing E. coli
(VTEC)
Faecal pathogens A
(AusDiagnostics)
∼3  h Multiplex
tandem PCR
No Centralised
laboratory
(high sample
throughput)
16 viruses, bacteria
and  parasites
Rotavirus  A, norovirus G1and G2, Adenovirus group
F  and G, Salmonella spp., Shigella spp., Campylobacter
spp., Clostridium difﬁcile (toxin B), Yersinia
enterocolitica, Aeromonas hydrophila, Giardia lamblia,
Cryptosporidium (parvum and hominis), Dientamoeba
fragilis, Entamoeba histolytica, Blastocystis hominis
XTAG GPP
(Luminex)
∼5  h Multiplex
rtPCR,
suspension
array
detection
FDA
approved CE
marked
Centralised
laboratory
(high sample
throughput)
15 viruses, bacteria
and  parasites
Adenovirus  40/41, Norovirus GI/GII, Rotavirus A,
Campylobacter spp., Clostridium difﬁcile (Toxin A/B),
Escherichia coli O157, Enterotoxigenic E. coli (ETEC)
LT/ST, Shiga-like Toxin producing E. coli (STEC)
stx1/stx2, Salmonella spp., Shigella spp., Vibrio cholera,
Yersinia enterocolitica, Giardia spp., Cryptosporidium
spp., Entamoeba histolytica
CLART  EnteroBac ∼5 h Multiplex
PCR and
array
detection
CE marked Near patient
(high sample
throughput)
8 bacterial
pathogens
Salmonella  spp., Aeromonas spp., Shigella spp.,
Escherichia coli [Enterohämorrhagic E. coli (EHEC),
Enteropathogeic E. coli (EPEC) Enterotoxic E. coli (ETEC)
and Enteroinvasive E. coli (EIEC)], Campylobacter spp.,
Campylobacter jejuni, Campylobacter coli, Clostridium
difﬁcile (toxin B), Yersinnia spp., Yersinia enterocolitica
Enteric Pathogens
[EP]  Test
(Nanosphere)
∼2  h PCR,
hybridisation
to gold
nanoparticle
No Near patient
(high sample
throughput)
9 viruses, bacteria
and  toxins
Norovirus,  Rotavirus Campylobacter spp., Salmonella
spp., Shigella spp. Shiga Toxin Gene (stx1and stx2),
Vibrio spp., Yersinia enterocolitica
Filmarray  GI panel
(Bioﬁre)
∼1  h Nested PCR,
Multiplex
rtPCR,
meltcurve
analysis
FDA
approved
Near patient
(low sample
throughput)
23 viruses, bacteria
and  parasites
Adenovirus  F40/41, Astrovirus, Norovirus GI/GII,
Rotavirus A, Sapovirus (I, II, IV and V), Campylobacter
spp. (jejuni, coli and upsaliensis), Clostridium difﬁcile
(Toxin A/B), Plesiomonas shigelloides, Salmonella spp.,
Yersinia  enterocolitica, Vibrio spp. (parahaemolyticus,
vulniﬁcus, and cholera), Vibrio cholera,
Enteroaggregative E. coli (EAEC), Enteropathogenic
E. coli (EPEC), Enterotoxigenic E. coli (ETEC) lt/st,
Shiga-like toxin-producing E. coli (STEC) stx1/stx2,
E. coli O157, Shigella/Enteroinvasive E. coli (EIEC),
Cryptosporidium spp., Cyclospora cayetanensis,
Entamoeba histolytica, Giardia lamblia
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reen [23,24]. This approach has been successfully applied for the
etection of fungal pathogens from blood, enteric protozoa from
linical stool samples and other diarrhoeal pathogens from stool
amples [24–26]. An advantage of this test is the ability to rapidly
etect a large number of viruses, bacteria and parasites. A disadvan-
age of this test is that nucleic acid must be extracted and puriﬁed
ff line prior to use of this test.
. End point PCR – array technologies
Traditional PCR and real-time PCR based assays are limited by
heir ability to only detect 5–6 analytes per test. While new adapta-
ions, such as tandem PCR above, may  help to increase the number
f analytes detected, alternative detection platforms are more com-
only used to achieve multiparametric detection of pathogens. For
xample, there are a number of commercially available tests for
he identiﬁcation of faecal pathogens, which utilise multiplex PCR
ollowed by hybridisation to microarray/macroarray. Examples of
ome of these technologies are outlined below.
.1. Luminex Gastrointestinal Pathogen Panel
The Food and Drug Association (FDA) approved and CE-IVD
arked Luminex Gastrointestinal Pathogen Panel (xTAG GPP) is a
ualitative assay which allows for the detection of a broad range of
irus, bacteria and parasites in a single test (Table 1). This test pro-
edure includes nucleic acid extraction, multiplex PCR and reverse
ranscriptase PCR, subsequent hybridisation to a bead array, and
etection on the Luminex 100/200 or Magpix instrument. Recent
tudies have demonstrated the test sensitivity range to be between
0 and 100%, depending on the pathogen present, and speciﬁcity
ange between 91 and 99% [27,28]. The main advantages of this test
re the high sample throughput that can be achieved; the number of
ifferent analytes detected by the test; and also the ability to deter-
ine co-infection in patients [29–31]. However, a disadvantage of
he test is it is not an integrated platform. There is a requirement
or an off line nucleic acid extraction and also post PCR ampliﬁca-
ion handling of samples which increases the potential likelihood
f cross contamination giving rise to false positives [30].
.2.  CLART EnteroBac
CLART  EnteroBac (Genomica, Madrid, Spain) is a PCR array based
echnology that allows for the detection and identiﬁcation of 8
acteria to the genus and species level (Table 1) [32]. The test is
roposed for use directly on stool without the requirement for
ny sample enrichment. The test procedure utilises DNA extrac-
ion, multiplex PCR, hybridisation to low density microarrays and
ubsequent automated reading and interpretation of results [32].
n advantage of this technology is that it is the high throughput and
nitial manufacture performance data is promising [33]. However,
 disadvantage of the CLART Enterobac test is that it is limited to
he detection of bacterial pathogens.
. Integrated platform tests
In the context of molecular diagnostics, platforms which are
ully integrated to generate “sample in to result out” offer signif-
cant advantages in a clinical setting. For example, they typically
equire less hands on time; are often more user friendly to perform;
educe the requirement for highly trained personnel; and with
utomated recording and reporting of results they are often less
ubjective. In recent years, many commercial entities have strived
o provide such platforms, and in the context of faecal pathogen
etection, a number of such tests are described below.on and Quantiﬁcation 1 (2014) 3–7
4.1. Enteric Pathogens (EP) Test Nanosphere’s Verigene
The Verigene Enteric Pathogens (EP) Test (Nanosphere) has been
developed for use on the FDA approved Verigene platform. Brieﬂy,
this approved platform consists of the Verigene Processor and a
Verigene reader. The Verigene processor is used for extraction and
puriﬁcation of nucleic acid, ampliﬁcation if required and hybrid-
isation of sample to gold nanoparticle conjugated capture probes
immobilised on a glass slide. Upon completion of hybridisation, the
slide is transferred to the Verigene Reader for result interpretation
[34]. The EP test, designed for use on stool, has the ability to iden-
tify a number of viruses and bacteria (and associated toxins) and
is reported to provide a result in approximately 2 h (Table 1). An
advantage of this kit is the little hands on time required to perform
the test and the fact it is integrated from sample to result. While
each Verigene reader can only process one sample at a time, sam-
ple throughput can be increased if multiple processors are linked
to each individual reader.
4.2.  Filmarray GI panel
The  Filmarray platform (Bioﬁre Diagnostics, Salt Lake City, UT,
USA) is a fully integrated system including sample preparation,
nested RT-PCR followed by multiplex PCR and detection by melt
curve analysis. The Filmarray GI panel, which was recently FDA
approved, is intended for use of the Filmarray platform and allows
for the detection of 23 viruses, bacterial and parasitic pathogens
(Table 1) [35]. An advantage of this kit is the little hands on time
required to perform the test and the fact it is integrated from sam-
ple to result [31]. Furthermore, the ﬁlmarray GI panel detects and
identiﬁes the greatest number of viruses, bacteria and parasites on
the market at present. However, a disadvantage of the Filmarray
platform is that sample throughput is low [36].
5. Future prospectives
This  review focuses on recent developments in commercially
available nucleic acid based tests for pathogens associated with
human gastroenteritis. Alternative technologies such as PCR mass
spectrometry and next generation sequencing also have the poten-
tial for use in this disease setting. For example, Abbott Molecular
has developed the CE-IVD marked Plex ID system which com-
bines PCR with electrospray ionisation mass spectrometry for the
detection of a wide range of microorganisms [37]. While there are
currently no commercially available kits for the speciﬁc detection
of microorganisms associated with human gastroenteritis based on
these platforms, such approaches will be developed further in the
future.
6. Concluding remarks
In  recent years, there has been a growing trend to adapt NAAT’s
to complement traditional microbiological testing methods, or
where possible bypass and replace such methods in the clinical set-
ting. This is partly due to the increased speciﬁcity, sensitivity and
turnaround time to result. However, the requirement for highly
trained personnel, cost and infrastructure requirements remain
limiting factors for routine use of NAAT’s in a clinical setting [38]. In
an effort to combat some of these limitations, multiplex assays, and
more recently integrated multiparametric platforms, have been
described for the identiﬁcation and management of syndromic
disease [31,39]. Owing to the wide spectrum of microorganisms
associated with gastroenteritis, rapid detection and identiﬁcation
of the causative agent of infection remains challenging. In this
disease setting, multiparametric tests which have the ability to
etecti
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dentify viruses, bacteria and parasites are particularly useful. They
an aid in rapid high throughput routine screening directly from
tool; monitor epidemiological outbreaks; and ultimately guide
atient therapy through improved antimicrobial stewardship and
anagement in a timely manner.
In this review, we have described a range of state of the art
ommercial gastroenteritis diagnostics tests which vary greatly in
oth the number and type of pathogens which can be detected
nd identiﬁed. The true clinical utility and validation of many of
hese tests remains unproven until more extensive peer reviewed
tudies deﬁning performance characteristics, including diagnostic
peciﬁcity and sensitivity are described. Further development of
utomated multiparametric integrated NAAT systems which can
dentify viruses, bacteria, parasites and also some drug resistance
arkers, will result in the routine use of molecular tests for gas-
roenteritis in a clinical setting in the near future.
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